The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients.

DOI IR (HANDLE) HANDLE Web Site Web Site View 2 Remaining Hide 15 References Open Access
  • So, Makiko
    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine
  • Miyamoto, Taito
    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine
  • Murakami, Ryusuke
    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine
  • Abiko, Kaoru
    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine
  • Hamanishi, Junzo
    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine
  • Baba, Tsukasa
    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine･Department of Obstetrics and Gynecology, Iwate Medical University Faculty of Medicine
  • Mandai, Masaki
    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine
  • 宮本, 泰斗
  • 濵西, 潤三
  • 万代, 昌紀
  • 80378736

Search this article

Description

Objective: In patients with recurrent ovarian cancer (ROC) in whom surgery is likely to render them disease-free, it is unclear whether secondary cytoreductive surgery (SCS) combined with chemotherapy is superior to chemotherapy alone. The aim of this study was to evaluate the 2 treatment options in Tian-model low-risk patients. Methods: We retrospectively reviewed 118 ROC cases treated in our hospital between 2004 and 2016. Of these, 52 platinum-sensitive cases were classified as low-risk (complete resection anticipated) using the Tian model. Prognostic factors were assessed with univariate and multivariate analysis using Cox's regression model. Progression-free survival (PFS) and overall survival (OS) were compared in patients treated with SCS plus chemotherapy (SCS group) and those treated with chemotherapy alone (chemotherapy group), using a propensity-score-based matching method. Results: By multivariate analysis, the only factor associated with better OS was SCS. PFS and OS were significantly longer in the SCS group compared to the chemotherapy group in the matched cohort (median PFS: 21.7 vs. 15.1 months, p=0.027 and median OS: 91.4 vs. 33.4 months, p=0.008, respectively). In cases with multiple-site recurrence, the SCS group also showed significantly longer OS than the chemotherapy group (median 91.4 vs. 34.8 months, p=0.022). In almost all SCS cases, cooperation was required from other departments, and operation time was lengthy (median 323 minutes); however, no serious complications occurred. Conclusion: SCS combined with chemotherapy results in better PFS and OS than chemotherapy alone in first platinum-sensitive ROC patients categorized as low-risk by Tian's model.

Journal

  • Journal of Gynecologic Oncology

    Journal of Gynecologic Oncology 30 (6), 2019-11

    Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

References(15)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top